Digital Health Investment Weekly Report (Issue 159): Global Funding, Partnerships, and M&A Highlights

Due to recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the homepage of the official account to get the latest trends and expert insights in the digital healthcare industry第一时间!

01 Global Digital Health Investment and Financing Overview

Precision Medicine Service Provider Caris Life Sciences Secures $168 Million in Financing

On April 7, precision medicine service provider Caris Life Sciences secured $168 million in funding, led by existing investor Braidwell, with participation from Perceptive Advisors, Woodline, and others. The funds will be used to comprehensively study cancer at the molecular level and achieve transformative applications of molecular science to unlock the full potential of precision medicine.

Novel Biologic Therapeutics Developer Merida Biosciences Secures $121 Million in Series A Funding

On April 8, Merida Biosciences, a developer of novel biotherapeutics, secured $121 million in Series A financing. The round was co-led by Bain Capital Life Sciences, BVF Partners, and Third Rock Ventures, with participation from GV and Perceptive Xontogeny Venture Funds. Merida has developed a new platform that precisely targets pathogenic antibodies driving various autoimmune and allergic diseases.

Cell Therapy Developer Solu Therapeutics Secures $41 Million in Series A Funding

On April 9, cell therapy developer Solu Therapeutics secured $41 million in Series A financing, led by five new investors including Eli Lilly and Company, as well as existing Solu investors Longwood Fund and DCVC Bio. The funding will be used to complete dose escalation and expansion of the company’s leading CCR2-CyTAC program, STX-0712, for the treatment of CMML, and to support the development of new drug candidates.

Healthcare Benefits Service Provider Thatch Secures $40 Million in Series B Funding

On April 4, Thatch, a healthcare benefits service provider, secured $40 million in Series B funding led by Index Ventures. Existing investors Andreessen Horowitz, PeopleTech Partners, General Catalyst, The General Partnership, and SemperVirens participated, along with new investor ADP Ventures. The company offers ICHRA plans, which allow employers to provide employees with tax-free allowances that can then be used to choose personalized health, dental, and vision benefits.

3D Printing Implant Supplier Restor3d Secures $38 Million in Financing

On April 4, 3D printing implant supplier Restor3d secured $38 million in funding, with participation from investors such as Summers Value Partners. This round of financing will drive the company’s continued growth and the launch of four groundbreaking 3D printing product lines in 2025 and 2026, accelerating the large-scale development and adoption of personalized orthopedic solutions.

Genetic and Assisted Reproductive Medical Service Provider Winsota Healthcare Secures $35 Million in Strategic Financing

On April 9, Yunchengda Medical, a provider of genetic and assisted reproductive medical services, received $35 million in strategic funding. This round of financing will mainly be used for the research and development of new technologies, intelligent upgrades, further refinement of service systems, and the expansion of a global assisted reproductive service network.

Heart Failure Treatment Device Developer Puzzle Medical Devices Secures CAD 43 Million in Financing

On April 9, Puzzle Medical Devices, a developer of heart failure treatment devices, secured CAD 43 million in funding led by KF Matheson and Desjardins Capital, with participation from Lumira Ventures, Longview Ventures, BDC Capital, and existing investors. The funds will be used to enhance Puzzle Medical's percutaneous cardiac pump and its new features, advance clinical studies to evaluate its safety and efficacy, and expand the team to support the company’s growth.

One-stop AI Medical Imaging Solution Provider Yinghe Yimai Secures Over RMB 100 Million in Series A Funding

On April 7, Yingu Medical Imaging, a one-stop AI medical imaging solutions provider, secured over RMB 100 million in its Series A round of financing, led by Yuan Yi Capital with strategic support from Dingrun Jiade, Kezhi Chuang'an, and others. This has injected strong momentum into Yingu Medical Imaging’s industrial layout in the AI medical imaging field.ThisThis round of financing will continue to accelerate the iteration of the "Ying He Mi Ya®" medical imaging base model, the industrialization layout of the medical imaging AI ecosystem, and the construction of the talent team.

Wearable Ultrasound Stimulation Platform Provider SecondWave Systems Secures $7 Million in Series A Funding

On April 8, SecondWave Systems, a provider of wearable ultrasound stimulation platforms, secured $7 million in Series A funding led by Treo Ventures and a major healthcare strategic company, with participation from Scientific Health Development and others. This round of financing will support SecondWave's next clinical study, building on the success of its first-in-human study, which demonstrated a significant reduction in rheumatoid arthritis disease activity.

Biotechnology Lab Automation Equipment Developer UniteLabs Secures €2.77 Million Pre-Seed Funding

On April 7, UniteLabs, a developer of biotechnology laboratory automation equipment, secured a pre-seed funding round of 2.77 million euros, led by Cavalry Ventures with participation from PUSH and others. UniteLabs' platform provides a standardized cloud interface, offering the technical foundation for efficient research and the integration of artificial intelligence into laboratory processes, enabling biotechnology research laboratories to achieve seamless connectivity and laboratory equipment automation.

IDT Edtech and Bioscience Reach Comprehensive Strategic Cooperation to Accelerate Local Innovation

On April 8, global oligonucleotide innovator IDT officially signed a comprehensive strategic cooperation agreement with Shanghai Baicheng Biotechnology to accelerate the implementation of localized innovative projects in China. This collaboration will integrate IDT's technological advantages with Baicheng Biotechnology’s localization capabilities, adopting innovative models such as talent exchange and joint research and development. It will fully oversee the operation of IDT’s core product lines while establishing a new business ecosystem. This in-depth partnership marks a key milestone in the development of both parties within China’s life science research and precision medicine sectors, strongly promoting industry innovation and technological breakthroughs.

ABL Bio Reaches Global Licensing Agreement with GSK, Paving Way for New Breakthroughs in CNS Field

On April 7, South Korean biotechnology company ABL Bio announced a global licensing agreement with global pharmaceutical giant GSK, involving an amount of up to £2.075 billion (approximately RMB 19.584 billion). This is the largest collaboration in the CNS (central nervous system) field this year. GSK will utilize ABL Bio's blood-brain barrier (BBB) shuttle platform Grabody-B to develop novel drugs for neurodegenerative diseases. The platform promotes drug penetration through the blood-brain barrier by targeting insulin-like growth factor 1 receptor (IGF1R), enabling efficient delivery to the brain. The collaboration covers new targets across various therapeutic modalities, including antibodies, polynucleotides, or oligonucleotides (such as siRNA and ASO), aiming to address significant unmet medical needs of patients with neurodegenerative diseases.

Novo Nordisk and Tencent Health Launch Strategic Cooperation to Build a New Digital Ecosystem for Obesity Prevention and Control

On April 7, Novo Nordisk, the global leader in obesity treatment, announced a strategic partnership with Tencent Health. Against the backdrop of China's national initiative to promote the "Year of Weight Management," the two parties will leverage the "Tencent Health" mini-program and "Tencent Medical Encyclopedia" to create a one-stop "Weight Management Knowledge and Service Zone." This initiative aims to help the public manage their weight scientifically and improve the accessibility of obesity diagnosis and treatment.

Activated Insights Acquires WeCare Connect

On April 9, Activated Insights, an information software developer, acquired WeCare Connect. The latter is a top provider of technology-driven communication and engagement solutions for long-term and post-acute care providers. WeCare Connect currently serves over 1,300 organizations, focusing on continuing care retirement communities and nonprofit senior care organizations, making it a highly complementary addition to Activated Insights' product suite and further expanding its influence in the elderly care market.

Digital Health Startup Transcarent Acquires Accolade

On April 8, digital health startup Transcarent completed the acquisition of Accolade for $621 million. Transcarent first announced the acquisition in January, stating that it had obtained all necessary shareholder and regulatory approvals to execute the transaction. Accolade is a digital healthcare company dedicated to helping self-insured enterprise employers enhance consumer experience by providing customers with a fixed "point of contact."

Musculoskeletal Implant Manufacturer Globus Medical Acquires Nevro

On April 4, musculoskeletal implant manufacturer Globus Medical acquired Nevro. Globus agreed to purchase all of Nevro's shares at $5.85 per share, with the total equity value amounting to approximately $250 million. Globus stated that this acquisition not only signifies a major expansion for the company but also brings a $2.5 billion market opportunity, broadening its product range in the neuromodulation field.

Healthcare and Health Product Promoter and Distributor JBM Acquires Tianxitang Pharmaceutical Factory

On April 3, JBM&M (02161.HK), a healthcare product promotion and distribution company, acquired 90% of Tianxitang Pharmaceutical Factory for a total consideration of HKD 1.71 billion. Tianxitang's flagship product, "Tianxitang Tianxi Pills," enjoys high brand recognition in Hong Kong and mainland China (especially in Guangdong Province). It is specifically designed to regulate the female menstrual cycle, promote reproductive health, and enhance blood circulation. This acquisition is expected to bring significant synergies to JBM&M, further solidifying its leading position in the branded traditional Chinese medicine market.

Comprehensive Healthcare Solutions Provider Fingerpaint Group Acquires BlackPoint Consulting Group

On April 3, Fingerpaint Group, a comprehensive healthcare solutions provider, acquired BlackPoint Consulting Group. This acquisition strengthens Fingerpaint Group's Integrated Center of Excellence for Market Access, equipping it with a full suite of capabilities to address the wide-ranging access and patient support challenges typically faced by life sciences companies.

Medical Device Manufacturer Boston Scientific Acquires Bolt Medical

On April 2, medical device manufacturer Boston Scientific announced the completion of its acquisition of Bolt Medical. The acquisition agreement was reached in early January, with a total transaction value of up to $664 million, including a $443 million upfront payment and up to $221 million in regulatory milestone payments. Bolt Medical is a medical device company specializing in intravascular lithotripsy (IVL) technology, and Boston Scientific previously held a 26% stake in the company. This acquisition will expand Boston Scientific’s portfolio of products in the cardiovascular treatment field, particularly in the treatment of coronary artery and peripheral artery diseases.

Advanced Therapy Initiation and Patient Solutions Provider AssistRx Acquires AllazoHealth

On April 2, AssistRx, a provider of advanced therapy initiation and patient solutions, acquired AllazoHealth. This asset acquisition will enhance the advanced solutions AssistRx offers to its life science organization clients. With the integration of AllazoHealth's assets, AssistRx further differentiates its accessibility, affordability, adherence, and engagement solutions through the latest technological advancements (artificial intelligence), allowing talent to better focus on people.

ArteryNet/Arterial Orange Industry Think Tank/Huaxing Capital/BGI Co-Win/Rock Health/Mobile Health News/Fierce Health, etc.

Compiled by: Huang Changjian‍‍‍

Share

Like

Tap to view